Administration Route: |
Oral |
Injection site: |
|
Frequency: |
Twice daily |
TGA approval date: |
13 May 2011 |
PBS listed: |
No |
Mechanism of action |
Fampridine is a formulation of 4-aminopyridine, a potassium channel blocker. It works by stopping potassium leaving nerve cells which have been damaged by MS so letting signals pass down the nerve more normally. Consequently, some people are able to walk better. |
%reduction in relapse rate, impact of progression |
This is a symptomatic treatment |
Pregnancy Category |
C |
Safe in Pregnancy |
Suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. |
Breastfeeding (information predominatly from LACTMED database) |
Fampridine is not recommended while breastfeeding |
Monitoring requirements |
|
Potential side effects (not a comprehensive list) |
Increased risk of urinary infections, headaches, feeling weak,anxiety, sore throat, nausea, vomiting, constipation, upset stomach, back pain, dizziness, feeling unsteady, tingling of the skin, minor shaking, worsening of facial nerve pain. |
Manufacturer |
Biogen |